Alvotech Sa

Organisation

9, Rue de Bitbourg, Luxembourg, Luxembourg, 1273

Headquarters

1012

Employees

Services

Industry

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Price

Target

Alvotech Sa (ALVO) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Alvotech Sa (ALVO) share price will touch around $18.83 in next 12-months.

Currently 11 wall-street analysts regularly analyze the financials of Alvotech Sa on a frequent basis to provide recommendations along with target share price. 11 analysts offering 12-month price forecasts for Alvotech Sa (ALVO) have a share price target of $18.83. This median of share price forecast represents a 432.01% upside from the latest price of $3.54 as on 21.03.26.

Alvotech Sa (ALVO) Share Price Forecast

Home

US Stocks

Alvotech Sa (ALVO)

Alvotech Sa Stock Forecast

Alvotech Sa Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Alvotech Sa (ALVO): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Alvotech Sa's share price and its median forecast price. As on 21.03.26, the difference is -69.94%

Alvotech Sa Forecast and Target Price

Alvotech Sa (ALVO) Share Price Forecast

Alvotech Sa (ALVO) Price vs Consensus Price Target

Alvotech Sa (ALVO) Share Price Forecast v/s Share Price Today

Alvotech Sa (ALVO): Difference between Current Price & Median Forecasted Price

Alvotech Sa (ALVO) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price